ng28ÄϹ¬ºÍ²³½¡Ðû²¼£¬ÈËÔ´»¯¿¹¿ÉÈÜÐÔ¾Û¼¯µí·ÛÑùÂÑ°×-¦Â (A¦Â)µ¥¿Ë¡¿¹Ìå “LEQEMBI? ¾²Âö×¢É䣨ÂØ¿¨Ä¹£º200 mg ¾²Âö×¢ÉäÓÃÒ©ºÍ Leqembi 500 mg ¾²Âö×¢ÉäÓÃÒ©£©ÔÚÈÕ±¾»ñÅú£¬ÓÃÓÚÑÓ»º°¢¶û´Äº£Ä¬²¡£¨AD£©ÒýÆðµÄÇá¶ÈÈÏÖªÕÏ°£¨MCI£©ºÍÇá¶È³Õ´ôÖ¢µÄ½øÕ¹¡£
LEQEMBIÊÇÒ»ÖÖÈËÔ´»¯ÃâÒßÇòÂѰצÃ1£¨IgG1£©µ¥¿Ë¡¿¹Ì壬Õë¶Ô¾Û¼¯µÄ¿ÉÈÜÐÔ£¨ÔÏËά*£©ºÍ²»¿ÉÈÜÐÔÐÎʽµÄ¦Âµí·ÛÑùÂÑ°×£¨A¦Â£©¡£LEQEMBIÕë¶Ô²¢Çå³ýÁ¬Ðø»ýÀÛµÄ×î¾ßÉñ¾¶¾ÐÔµÄA¦ÂÐÎʽ£¬²¢Çå³ýÏÖÓа߿飬ÒÔÖÎÁÆÕâÖÖ½¥½øµÄÂýÐÔ¼²²¡¡£¼Ì 2023 Äê 7 ÔÂÔÚÃÀ¹ú»ñµÃ¹Å°åÅú×¼Ö®ºó£¬ÈÕ±¾Êǵڶþ¸ö»ñµÃÅú×¼µÄ¹ú¼Ò¡£
LEQEMBIµÄ¹Å°åÅú×¼ÊÇ»ùÓÚng28ÄϹ¬µÄ´óÐÍÈ«ÇòClarity ADÁÙ´²ÊÔÑéµÄIIIÆÚÊý¾Ý¡£ÔÚ¸ÃÊÔÑéÖУ¬LEQEMBIµÖ´ïÁËÆäÖ÷ÒªÖÕµãºÍËùÓÐÒªº¦´ÎÒªÖÕµãµÄͳ¼ÆѧÒâÒåÉϵĽá¹û£¬²¢Ö¤ÊµÁËLEQEMBIµÄÁÙ´²»ñÒæ¡£Ö÷ÒªÖÕµãÊÇÈ«ÇòÈÏÖªºÍ¹¦Ð§Á¿±í£¬¼´ÁÙ´²³Õ´ôÖ¢ÆÀ·Ö×Ü±í£¨CDR-SB£©¡£Óëο½å¼ÁÏà±È£¬LEQEMBIÖÎÁÆÔÚ18¸öÔÂʱ¼õÉÙÁËCDR-SBµÄÁÙ´²Ï½µ27%¡£±ðµÄ£¬ÓÉAD¿´»¤ÕßÆÀ¹ÀµÄ´ÎÒªÖյ㰢¶û´Äº£Ä¬²¡Ð×÷Ñо¿×é-Çá¶ÈÈÏÖªÕÏ°-ÈÕ³£Éú»îÄÜÁ¦Á¿±íÆÀ·Ö£¨ADCS MCI-ADL£©ÏÔʾ³ö37%µÄÏÔÖøͳ¼Æѧ»ñÒæ¡£ÕâȨºâµÄÊÇ»¼Õ߶ÀÁ¢ÔË×÷µÄÄÜÁ¦£¬°üÀ¨Äܹ»´©Ò¡¢Î¹Ê³ºÍ¼ÓÈëÉçÇøÔ˶¯¡£Clarity ADÑо¿µÄÈ«²¿½á¹ûÔÚ2022Äê°¢¶û´Äº£Ä¬²¡ÁÙ´²ÊÔÑ飨CTAD£©¼¯»áÉÏÐû²¼£¬²¢Í¬Ê±Ðû²¼ÔÚ2022Äê11ÔÂ29ÈÕµÄͬÐÐÆÀÉóҽѧÔÓÖ¾¡¶ÐÂÓ¢¸ñÀ¼Ò½Ñ§ÔÓÖ¾¡·ÉÏ¡£
ng28ÄϹ¬Ê×ϯִÐйÙÄÚÌÙÇç·òÌåÏÖ£¬¡°½ñÌ죬LEQEMBI »ñµÃÅú×¼£¬³ÉΪÈÕ±¾Ê׸ö»ñÅúµÄ¿¹µí·ÛÑùÂÑ°×°¢¶û´Äº£Ä¬²¡ÖÎÁÆÒ©Îï¡£¸ÃÒ©ÎïÔÚ°¢¶û´Äº£Ä¬²¡µÄÔçÆÚºÍÇá¶È³Õ´ô½×¶Î¿É½µµÍ¼²²¡½øÕ¹Ëٶȣ¬¼õ»ºÈÏÖª¹¦Ð§Ë𺦡£ÎÒÃÇÏàÐÅ£¬ÎÒÃÇÒѾÏÆ¿ªÁË°¢¶û´Äº£Ä¬²¡ÖÎÁÆÊ·ÉÏеÄÒ»Ò³¡£°¢¶û´Äº£Ä¬²¡ÊÇÒ»ÖÖ½¥½øÐÔµÄÑÏÖؼ²²¡£¬²»µ«»á¶Ô»¼Õß¼°Æ令Àíͬ°éÔì³ÉÑÏÖØË𺦺͵£¸º£¬»¹»á¶ÔÕû¸öÉç»á±¬·¢¾Þ´óÓ°Ï죬×ÔÎÒÃÇÔÚÖþ²¨Ñо¿ÊÒ¿ªÊ¼³Õ´ôÖ¢Ñо¿ÒÔÀ´Ô¼ 40 Äê¼ä£¬ng28ÄϹ¬Ò»Ö±Óë³Õ´ôÖ¢»¼Õß¼°Æ令Àíͬ°é¼á³Ö»¥¶¯£¬²¢Å¬Á¦Á˽âËûÃǵÄÕæÇиÐÊÜ¡£Îª´Ë£¬ÎÒÃDz»¾øÌôÕ½£¬¿ª·¢Äܹ»´Ó»ù´¡ÉϽâ¾ö°¢¶û´Äº£Ä¬²¡²¡ÀíÎÊÌâµÄÖÎÁÆÒ©Îï¡£ÎÒÃÇÖÂÁ¦ÓÚ½« LEQEMBI ×÷ΪÏû³ý²¡ÒòµÄÐÂÁÆ·¨£¬ÌṩӦÓÐÐèÒªµÄÔçÆÚ°¢¶û´Äº£Ä¬²¡»¼Õß¼°Æä¼ÒÊô¡£Í¨¹ýÕâЩŬÁ¦£¬ÎÒÃǵÄÄ¿±êÊǶÔÈÕ±¾Éç»áÖÐΧÈƳմôÖ¢µÄÎÊÌⱬ·¢»ý¼«Ó°Ï씡£
²³½¡×ܲüæÊ×ϯִÐйÙChristopher A. ViehbacherÌåÏÖ£º”»ñµÃÅú×¼ºó£¬ÎÒÃǽ«ÄÜÓëng28ÄϹ¬Ò»Æð×ÊÖú½â¾ö°¢¶û´Äº£Ä¬²¡¶Ô»¼ÕßÔì³ÉµÄÆÆ»µÐÔÓ°Ï죬ÒÔ¼°¸ø»¤Àíͬ°é´øÀ´µÄÇé¸Ð¡¢Éç»áºÍ¾¼Ãµ£¸º¡£ÕâÊDz³½¡ºÍng28ÄϹ¬Îª¿ª´´ÖÎÁÆÕâÖÖÓ°ÏìÊý°ÙÍòÈ˵ļ²²¡µÄÐÂʱ´ú¶øÂõ³öµÄÖØÒªÒ»²½¡£ÎÒÃÇÆÚ´ýÓëng28ÄϹ¬Ð¯ÊÖÏàÖú£¬ÔÚÃÀ¹úºÍÈÕ±¾»ñÅúµÄ»ù´¡ÉÏÔÙ½ÓÔÙÀ÷£¬ÎªÈ«Çò»¼Õß¼°Æä¼ÒÍ¥´øÀ´ÕâһѡÔñ¡£¡°
ƾ¾ÝºñÉúÀͶ¯Ê¡»®¶¨µÄÅú×¼Ìõ¼þ£¬ÔÚÉÏÊкó»ýÀÛÒ»¶¨ÃüÁ¿µÄ»¼ÕßÊý¾Ý֮ǰ£¬ng28ÄϹ¬½«¶ÔËùÓÐʹÓà LEQEMBI µÄ»¼Õß½øÐÐÉÏÊкóÌØÊâÓÃ;½á¹ûÊӲ죨ȫ²¡Àý¼à²â£©¡£±ðµÄ£¬»¹½«Æ¾¾Ý°üװ˵Ã÷ÊéºÏÀíÍƹãʹÓà LEQEMBI £¬²¢ÎªÒ½ÁƱ£½¡×¨ÒµÈËÔ±±àдÅàѵÖÊÁÏ£¬ÒÔÐÖúÖÎÀíºÍ¼à²âµí·ÛÑùÂÑ°×Ïà¹Ø³ÉÏñÒì³££¨ARIA£©¡£
LEQEMBIµÄÈ«Çò¿ª·¢ºÍ¼à¹ÜÌá½»ÓÉng28ÄϹ¬Ö÷µ¼£¬¶ø²úÆ·ÔòÓÉng28ÄϹ¬ºÍ²³½¡ÅäºÏÉÌÒµ»¯ºÍÍƹ㡣ÆäÖУ¬ng28ÄϹ¬ÓµÓÐ×îÖÕ¾ö²ßȨ¡£ÔÚÈÕ±¾£¬ng28ÄϹ¬ºÍ²³½¡ÈÕ±¾½«ÅäºÏÍƹã LEQEMBI£¬ng28ÄϹ¬½«×÷ΪӪÏúÊÚȨ³ÖÓÐÈË·ÖÏú¸Ã²úÆ·¡£
Media Contacts: Eisai Eisai Co., Ltd. Public Relations Department TEL: +81 (0)3-3817-5120
Eisai Inc. (U.S.) Libby Holman + 1-201-753-1945 Libby_Holman@eisai.com
Biogen Inc. Jack Cox + 1 781-464-3260 public.affairs@biogen.com
Investor Contacts:? Eisai Co., Ltd. Investor Relations Department TEL: +81 (0) 3-3817-5122
Biogen Inc. Chuck Triano + 1-781-464-2442 IR@biogen.com